| The Hippo pathway component TAZ promotes immune evasion in human cancer through PD-L1 HJ Janse van Rensburg, T Azad, M Ling, Y Hao, B Snetsinger, P Khanal, ... Cancer research 78 (6), 1457-1470, 2018 | 267 | 2018 |
| A LATS biosensor screen identifies VEGFR as a regulator of the Hippo pathway in angiogenesis T Azad, HJ Janse van Rensburg, ED Lightbody, B Neveu, A Champagne, ... Nature communications 9 (1), 1061, 2018 | 157 | 2018 |
| Split-luciferase complementary assay: applications, recent developments, and future perspectives T Azad, A Tashakor, S Hosseinkhani Analytical and bioanalytical chemistry 406, 5541-5560, 2014 | 139 | 2014 |
| The role of YAP and TAZ in angiogenesis and vascular mimicry T Azad, M Ghahremani, X Yang Cells 8 (5), 407, 2019 | 89 | 2019 |
| PI3K positively regulates YAP and TAZ in mammary tumorigenesis through multiple signaling pathways Y Zhao, T Montminy, T Azad, E Lightbody, Y Hao, S SenGupta, E Asselin, ... Molecular Cancer Research 16 (6), 1046-1058, 2018 | 71 | 2018 |
| Identification of Celastrol as a Novel YAP-TEAD Inhibitor for Cancer Therapy by High Throughput Screening with Ultrasensitive YAP/TAZ–TEAD Biosensors K Nouri, T Azad, M Ling, HJJ van Rensburg, A Pipchuk, H Shen, Y Hao, ... Cancers 11 (10), 1596, 2019 | 66 | 2019 |
| Industrial applications of immobilized nano-biocatalysts M Razzaghi, A Homaei, F Vianello, T Azad, T Sharma, AK Nadda, ... Bioprocess and Biosystems Engineering, 1-20, 2022 | 63 | 2022 |
| A gain-of-functional screen identifies the Hippo pathway as a central mediator of receptor tyrosine kinases during tumorigenesis T Azad, K Nouri, HJ Janse van Rensburg, SM Maritan, L Wu, Y Hao, ... Oncogene 39 (2), 334-355, 2020 | 63 | 2020 |
| A kinome-wide screen using a NanoLuc LATS luminescent biosensor identifies ALK as a novel regulator of the Hippo pathway in tumorigenesis and immune evasion K Nouri, T Azad, E Lightbody, P Khanal, CJ Nicol, X Yang The FASEB Journal 33 (11), 12487, 2019 | 44 | 2019 |
| Virally programmed extracellular vesicles sensitize cancer cells to oncolytic virus and small molecule therapy ME Wedge, VA Jennings, MJF Crupi, J Poutou, T Jamieson, A Pelin, ... Nature communications 13 (1), 1898, 2022 | 38 | 2022 |
| Synthetic peptides that antagonize the angiotensin-converting enzyme-2 (ACE-2) interaction with SARS-CoV-2 receptor binding spike protein A Sadremomtaz, ZM Al-Dahmani, AJ Ruiz-Moreno, A Monti, C Wang, ... Journal of medicinal chemistry 65 (4), 2836-2847, 2021 | 37 | 2021 |
| Characterization of critical determinants of ACE2–SARS CoV-2 RBD interaction EEF Brown, R Rezaei, TR Jamieson, J Dave, NT Martin, R Singaravelu, ... International Journal of Molecular Sciences 22 (5), 2268, 2021 | 37 | 2021 |
| SARS-CoV-2 S1 NanoBiT: A nanoluciferase complementation-based biosensor to rapidly probe SARS-CoV-2 receptor recognition T Azad, R Singaravelu, EEF Fekete, Z Taha, R Rezaei, R Arulanandam, ... Biosensors and Bioelectronics 180, 113122, 2021 | 30 | 2021 |
| Nanoluciferase complementation-based bioreporter reveals the importance of N-linked glycosylation of SARS-CoV-2 S for viral entry T Azad, R Singaravelu, Z Taha, TR Jamieson, S Boulton, MJF Crupi, ... Molecular Therapy, 2021 | 28 | 2021 |
| Implications for SARS-CoV-2 vaccine design: Fusion of spike glycoprotein transmembrane domain to receptor-binding domain induces trimerization T Azad, R Singaravelu, MJF Crupi, T Jamieson, J Dave, EEF Brown, ... Membranes 10 (9), 215, 2020 | 28 | 2020 |
| Hippo signaling pathway as a central mediator of receptors tyrosine kinases (RTKs) in tumorigenesis T Azad, R Rezaei, A Surendran, R Singaravelu, S Boulton, J Dave, ... Cancers 12 (8), 2042, 2020 | 28 | 2020 |
| Antiviral potential of the antimicrobial drug atovaquone against SARS-CoV-2 and emerging variants of concern ME Carter-Timofte, R Arulanandam, N Kurmasheva, K Fu, G Laroche, ... ACS infectious diseases 7 (11), 3034-3051, 2021 | 25 | 2021 |
| Single-dose replicating poxvirus vector-based RBD vaccine drives robust humoral and T cell immune response against SARS-CoV-2 infection S Boulton, J Poutou, NT Martin, T Azad, R Singaravelu, MJF Crupi, ... Molecular Therapy 30 (5), 1885-1896, 2022 | 22 | 2022 |
| Synthetic virology approaches to improve the safety and efficacy of oncolytic virus therapies T Azad, R Rezaei, R Singaravelu, A Pelin, S Boulton, J Petryk, KA Onsu, ... Nature communications 14 (1), 3035, 2023 | 21 | 2023 |
| Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer MJF Crupi, Z Taha, TJA Janssen, J Petryk, S Boulton, N Alluqmani, ... Frontiers in Immunology 13, 1029269, 2022 | 20 | 2022 |
Xiaolong YangQueen's UniversityVerified email at queensu.ca